Comparison · NCT03230838-sae
Ceftolozane/Tazobactam vs Meropenem: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ceftolozane/Tazobactam vs Meropenem: serious adverse events. Trial comparisons, record NCT03230838-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03230838-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.03 | 0.0103 | 0.0845 | wilson | |
| Risk in group 2 | 0.0606 | 0.0168 | 0.196 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0306 | -0.167 | 0.0393 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.495 | 0.0864 | 2.84 | log | |
| Odds ratio, group 1 over group 2 | 0.479 | 0.0766 | 3 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Ceftolozane/Tazobactam than on Meropenem | 32.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ceftolozane/Tazobactam | Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum 1 g and 0.5 g/dose) administered IV every 8 hours for 7-14 days. | 3 | 100 | EG000 |
| Group 2 | Meropenem | Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for 7-14 days | 2 | 33 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse Events (AEs): From treatment (Day 1) up to 88 days. All-cause mortality: From randomization (Day 1) up to 88 days.
Source ClinicalTrials.gov
Trial
- Title
- MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
- NCT number
- NCT03230838
- Phases
- PHASE2
- Conditions
- Complicated Urinary Tract Infection, Pyelonephritis
- Interventions
- Ceftolozane/Tazobactam, Meropenem
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2021-12-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03230838?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03230838-sae